Table 2.
Baseline variables according to technical failure or MACE.
| Study Variable | PD Failure | MACE | |||||
|---|---|---|---|---|---|---|---|
| No (n = 34) |
Yes (n = 24) |
p | No (n = 31) |
Yes (n = 27) |
p | ||
| Anthropometric and Clinical data |
Women | 10 (29) | 8 (33) | ns | 12 (39) | 6 (22) | ns |
| Age (years old) | 51.0 (37.8–65.5) | 65.0 (53.5–71.8) | 0.006 | 51.0 (37.0–63.0) | 67.0 (52.0–72.0) | 0.003 | |
| Diabetes mellitus | 10 (29) | 7 (29) | ns | 3 (10) | 14 (52) | <0.001 | |
| Arterial hypertension | 21 (66) | 14 (61) | ns | 19 (63) | 16 (64) | ns | |
| Coronary ischemic disease | 10 (30) | 7 (29) | ns | 0 (0) | 17 (65) | <0.001 | |
| Cerebrovascular disease | 3 (9) | 1 (4) | ns | 0 (0) | 4 (15) | 0.038 | |
| Cardiac failure | 3 (9) | 3 (12) | ns | 0 (0) | 6 (23) | 0.006 | |
| Peripheral arterial disease | 7 (21) | 10 (42) | ns | 0 (0) | 17 (63) | <0.001 | |
| rGFR (mL/min/1.73 m2) | 7.9 (5.6–10.2) | 6.1 (2.6–10.3) | ns | 8.9 (5.3–10.4) | 6.0 (2.6–9.3) | ns | |
| Residual Diuresis (mL) | 1700 (1225–2350) | 1500 (600–2500) | ns | 1700 (1300–2400) | 1500 (1000–2350) | ns | |
| PD and Therapeutics Prescription |
Icodextrin | 14 (41) | 5 (21) | ns | 10 (32) | 9 (33) | ns |
| Use of amino acid solution | 2 (6) | 1 (4) | ns | 1 (3) | 2 (7) | ns | |
| Glucose applied | 120.0 (90.0–120.0) | 120.0 (120.0–143.8) | ns | 120.0 (90.0–135.0) | 120.0 (90.0–120.0) | ns | |
| Spironolactone | 9 (27) | 9 (38) | ns | 8 (26) | 10 (37) | ns | |
| Beta–blockers | 7 (21) | 5 (21) | ns | 2 (6) | 10 (37) | 0.004 | |
| Calcium channels blockers | 12 (35) | 18 (75) | 0.003 | 16 (52) | 14 (52) | ns | |
| Vitamin D analogues | 26 (77) | 18 (75) | ns | 23 (74) | 21 (78) | ns | |
| Non–calcium Phosphate binders | 9 (27) | 11 (46) | ns | 9 (29) | 11 (41) | ns | |
| Vitamin D3 supplements | 24 (71) | 17 (71) | ns | 20 (64) | 21 (78) | ns | |
| Cinacalcet | 8 (24) | 7 (29) | ns | 9 (29) | 6 (22) | ns | |
| Antiplatelet therapy | 10 (30) | 8 (33) | ns | 0 (0) | 18 (69) | <0.001 | |
| Statins | 10 (30) | 8 (33) | ns | 0 (0) | 18 (69) | <0.001 | |
| Erythropoietin/darbepoetin | 17 (50) | 17 (71) | ns | 15 (48) | 19 (70) | ns | |
| PD-related parameters, Frailty | Peritoneal transport (High) | 20 (59) | 14 (58) | ns | 19 (61) | 15 (56) | ns |
| CA 125 (UI/L) | 14.3 (9.8–25.0) | 25.2 (13.5–36.5) | ns | 15.6 (10.5–32.3) | 16.9 (12.0–36.9) | ns | |
| nPCR (g/Kg/day) | 1.0 (0.81–1.1) | 0.87 (0.77–1.1) | ns | 1.1 (0.88–1.2) | 0.83 (0.78–1.0) | 0.023 | |
| Kt/V | 2.9 (2.1–3.3) | 2.4 (1.9–2.9) | ns | 2.9 (2.4–3.4) | 2.4 (1.8–3.1) | 0.017 | |
| Frail | 4 (12) | 7 (29) | ns | 3 (10) | 8 (30) | ns | |
| Score de Edmonton | 2 (2–3) | 3.5 (2–6) | 0.038 | 2 (2–3) | 4 (2–6) | <0.001 | |
| Membrane Fibrosis and Serum biomarkers |
α–Klotho (pg/mL) | 779 (589–1016) | 724 (626–1090) | ns | 803 (640–1119) | 698 (548–958) | ns |
| Galectin–3 (ng/mL) | 9.4 (7.50–10.9) | 10.4 (9.2–11.0) | 0.048 | 9.9 (8.6–10.8) | 10.2 (8.6–11.1) | ns | |
| FGF21(pg/mL) | 1324 (834–2226) | 1435 (980–3135) | ns | 1410 (967–2061) | 1336 (921–2507) | ns | |
| FGF23 (pg/mL) | 748.9 (525.9–862.4) | 744.2 (649.2–848.6) | ns | 685.9 (578.3–858.8) | 761.9 (570.9–850.5) | ns | |
| TWEAK (pg/mL) | 0.14 (0.06–0.49] | 0.12 (0.05–0.28) | ns | 0.11 (0.06–0.48) | 0.16 (0.06–0.27) | ns | |
| TNF–α (pg/mL) | 0.18 (0.13–0.24) | 0.16 (0.14–0.20) | ns | 0.17 (0.12–0.19) | 0.17 (0.15–0.25) | ns | |
| hs–CRP (μg/mL) | 0.35 (0.17–0.48) | 0.39 (0.17–0.90) | ns | 0.39 (0.16–0.54) | 0.35 (0.19–0.63) | ns | |
| Peritoneal membrane fibrosis | 13 (38) | 9 (38) | ns | 5 (16) | 17 (63) | <0.001 | |
| STM | 95.0 (40.0–190.0) | 60.0 (20.0–200.0) | ns | 60.0 (30.0–110.0) | 190.0 (50.0–200.0) | 0.004 | |
| α–Klotho < 742 pg/mL | 16 (47) | 13 (54) | ns | 12 (39) | 17 (63) | ns | |
Data are present as median (IQR) or n (%). PD—peritoneal dialysis; n—number of individuals; ns—non-significant; nPCR—normalized protein catabolic rate; Kt/V—Dialysis efficacy index; rGFR—residual glomerular filtration rate; CA125—cancer antigen 125; FGF21—Fibroblast growth factor 21; FGF23—Fibroblast growth factor 23 c-terminal; TWEAK—Tumor necrosis factor-like weak inducer of apoptosis; TNFα—Tumor necrosis factor α; hs-CRP—ultra-sensitive C-reactive protein; STM—submesothelial compact zone thickness.